Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483. 1998

E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
Thomas E Starzl Transplantation Institute, University of Pittsburgh, PA 15213-2582, USA.

BACKGROUND Prostaglandin has been reported to have protective effects against liver injury. Use of this agent in clinical settings, however, is limited because of drug-related side effects. This study investigated whether misoprostol, prostaglandin E1 analogue, and OP-41483, prostaglandin I2 analogue, which have fewer adverse effects with a longer half-life, attenuate ischemic liver damage. METHODS Thirty beagle dogs underwent 2 hours of hepatic vascular exclusion using venovenous bypass. Misoprostol was administered intravenously for 30 minutes before ischemia and for 3 hours after reperfusion. OP-41483 was administered intraportally for 30 minutes before ischemia (2 microg/kg/min) and for 3 hours after reperfusion (0.5 microg/kg/min). Animals were divided into five groups: untreated control group (n=10); high-dose misoprostol (total 100 microg/kg) group (MP-H, n=5); middle-dose misoprostol (50 microg/kg) group (MP-M, n=5); low-dose misoprostol (25 microg/kg) group (MP-L, n=5); and OP-41483 group (OP, n=5). Animal survival, hepatic tissue blood flow (HTBF), liver function, and histology were analyzed. RESULTS Two-week animal survival rates were 30% in control, 60% in MP-H, 100% in MP-M, 80% in MP-L, and 100% in OP. The treatments with prostaglandin analogues improved HTBF, and attenuated liver enzyme release, adenine nucleotrides degradation, and histologic abnormalities. In contrast to the MP-H animals that exhibited unstable cardiovascular systems, the MP-M, MP-L, and OP animals experienced only transient hypotension. CONCLUSIONS These results indicate that misoprostol and OP-41483 prevent ischemic liver damage, although careful dose adjustment of misoprostol is required to obtain the best protection with minimal side effects.

UI MeSH Term Description Entries
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D011465 Prostaglandins, Synthetic Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity. PG Analog,PG Analogs,Prostaglandin Analog,Prostaglandin Analogs,Prostaglandin Analogue,Synthetic Prostaglandin,Prostaglandin Analogues,Synthetic Prostaglandins,Analog, PG,Analog, Prostaglandin,Analogs, PG,Analogs, Prostaglandin,Analogue, Prostaglandin,Analogues, Prostaglandin,Prostaglandin, Synthetic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses

Related Publications

E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
June 1985, Burns, including thermal injury,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
September 1989, Clinical pharmacy,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
October 1993, Cryobiology,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
May 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
June 1993, Fukushima journal of medical science,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
February 1988, Kokyu to junkan. Respiration & circulation,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
December 1994, Journal of anesthesia,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
July 1989, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
April 2001, Medical journal, Armed Forces India,
E Totsuka, and S Todo, and Y Zhu, and N Ishizaki, and Y Kawashima, and M B Jin, and A Urakami, and T Shimamura, and T E Starzl
June 1995, Journal of the American College of Surgeons,
Copied contents to your clipboard!